JP2015522542A - 非小細胞肺癌を処置するための方法 - Google Patents

非小細胞肺癌を処置するための方法 Download PDF

Info

Publication number
JP2015522542A
JP2015522542A JP2015512895A JP2015512895A JP2015522542A JP 2015522542 A JP2015522542 A JP 2015522542A JP 2015512895 A JP2015512895 A JP 2015512895A JP 2015512895 A JP2015512895 A JP 2015512895A JP 2015522542 A JP2015522542 A JP 2015522542A
Authority
JP
Japan
Prior art keywords
clusterin
lung cancer
small cell
cell lung
nucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015512895A
Other languages
English (en)
Japanese (ja)
Inventor
ドゥクシン、チェン
テスラー、ショーシ
Original Assignee
テバ ファーマシューティカル インダストリーズ リミティド
テバ ファーマシューティカル インダストリーズ リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テバ ファーマシューティカル インダストリーズ リミティド, テバ ファーマシューティカル インダストリーズ リミティド filed Critical テバ ファーマシューティカル インダストリーズ リミティド
Publication of JP2015522542A publication Critical patent/JP2015522542A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G01N33/5752—

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2015512895A 2012-05-18 2013-05-17 非小細胞肺癌を処置するための方法 Pending JP2015522542A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261649092P 2012-05-18 2012-05-18
US61/649,092 2012-05-18
PCT/US2013/041652 WO2013173757A1 (en) 2012-05-18 2013-05-17 Method for treating non-small cell lung cancer

Publications (1)

Publication Number Publication Date
JP2015522542A true JP2015522542A (ja) 2015-08-06

Family

ID=49581824

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015512895A Pending JP2015522542A (ja) 2012-05-18 2013-05-17 非小細胞肺癌を処置するための方法

Country Status (17)

Country Link
US (1) US20130310440A1 (enExample)
EP (1) EP2849761A1 (enExample)
JP (1) JP2015522542A (enExample)
KR (1) KR20150024843A (enExample)
CN (1) CN104684564A (enExample)
AR (1) AR091090A1 (enExample)
AU (1) AU2013262589A1 (enExample)
BR (1) BR112014028787A2 (enExample)
CA (1) CA2874092A1 (enExample)
EA (1) EA201492148A1 (enExample)
IL (1) IL235459A0 (enExample)
IN (1) IN2014DN10390A (enExample)
PH (1) PH12014502569A1 (enExample)
SG (1) SG11201407649RA (enExample)
TW (1) TW201402132A (enExample)
UY (1) UY34812A (enExample)
WO (1) WO2013173757A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU767133B2 (en) 1999-02-26 2003-10-30 University Of British Columbia, The TRPM-2 antisense therapy
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
SI3155965T1 (sl) 2010-05-08 2025-10-30 The Regents Of The University Of California Postopek za radiofrekvenčno zaznavanje in aparat za zgodnje odkrivanje razjede zaradi pritiska
JP2014509608A (ja) 2011-03-15 2014-04-21 ザ ユニバーシティ オブ ブリティッシュ コロンビア 前立腺癌を治療するための、抗クラステリンオリゴヌクレオチドとｈｓｐ９０阻害剤との併用
CN104473973B (zh) * 2014-12-19 2015-08-05 山东创新药物研发有限公司 一株戈氏梭菌驯化株的应用
CA2982249C (en) 2015-04-24 2019-12-31 Bruin Biometrics, Llc Apparatus and methods for determining damaged tissue using sub-epidermal moisture measurements
PL3515306T3 (pl) 2017-02-03 2025-03-17 Bbi Medical Innovations, Llc Pomiar podatności na owrzodzenie stopy cukrzycowej
US11337651B2 (en) 2017-02-03 2022-05-24 Bruin Biometrics, Llc Measurement of edema
ES2966366T3 (es) 2017-02-03 2024-04-22 Bbi Medical Innovations Llc Medición de viabilidad tisular
WO2019099812A1 (en) 2017-11-16 2019-05-23 Bruin Biometrics, Llc Providing a continuity of care across multiple care settings
US20190211044A1 (en) * 2018-01-05 2019-07-11 LifeUnit Inc. Adjuvant Chemicals that Prevent Drug Tolerance and Persister Formation by Bacteria
HUE066478T2 (hu) 2018-02-09 2024-08-28 Bruin Biometrics Llc Szöveti károsodás észlelése
EP4283799B1 (en) 2018-10-11 2025-01-15 Bruin Biometrics, LLC Device with disposable element
WO2022169850A1 (en) 2021-02-03 2022-08-11 Bruin Biometrics, Llc Methods of treating deep and early-stage pressure induced tissue damage

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900187B2 (en) * 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
US8710020B2 (en) * 2004-04-02 2014-04-29 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
WO2009155381A1 (en) * 2008-06-18 2009-12-23 Abbott Laboratories P/gf-1 companion diagnostic methods and products
SG194931A1 (en) * 2011-05-19 2013-12-30 Teva Pharma Method for treating non-small cell lung cancer

Also Published As

Publication number Publication date
WO2013173757A8 (en) 2015-04-30
EP2849761A1 (en) 2015-03-25
KR20150024843A (ko) 2015-03-09
IN2014DN10390A (enExample) 2015-08-14
CA2874092A1 (en) 2013-11-21
UY34812A (es) 2013-12-31
WO2013173757A1 (en) 2013-11-21
EA201492148A1 (ru) 2015-04-30
CN104684564A (zh) 2015-06-03
AU2013262589A1 (en) 2015-01-22
IL235459A0 (en) 2014-12-31
PH12014502569A1 (en) 2015-01-21
BR112014028787A2 (pt) 2017-06-27
US20130310440A1 (en) 2013-11-21
TW201402132A (zh) 2014-01-16
AR091090A1 (es) 2014-12-30
SG11201407649RA (en) 2014-12-30

Similar Documents

Publication Publication Date Title
JP2015522542A (ja) 非小細胞肺癌を処置するための方法
JP2014520081A (ja) 非小細胞肺癌を処置するための方法
Diep et al. Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells
Gatzemeier et al. Randomized phase II trial of gemcitabine–cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer
JP6242213B2 (ja) 薬物送達および治療用薬剤の有効性を向上させる方法
JP5926724B2 (ja) がんを処置する方法
Yuan et al. Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial
KR20160132496A (ko) 초분자 조합 치료제
KR20200014298A (ko) Her2 양성 암의 치료
CN110072550A (zh) 用于治疗脑癌的组合疗法
Chu et al. Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies
CN104039343A (zh) 基于he4治疗恶性疾病
Gauler et al. Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC)
JP6587142B2 (ja) マイクロｒｎａからなるがん治療剤
CN107750165A (zh) 借助塞里班土单抗的组合治疗
Gao et al. High glucose-upregulated PD-L1 expression through RAS signaling-driven downregulation of PTRH1 leads to suppression of T cell cytotoxic function in tumor environment
JPWO2014126233A6 (ja) マイクロｒｎａの測定方法、並びに、がん治療剤及びこれを含有するがん治療のための医薬組成物
Ardalan et al. A phase I study of 5-fluorouracil/leucovorin and arsenic trioxide for patients with refractory/relapsed colorectal carcinoma
Chi et al. Phase I dose-finding study of sorafenib with FOLFOX4 as first-line treatment in patients with unresectable locally advanced or metastatic gastric cancer
Piha-Paul et al. Phase I dose-escalation trial of AMXT 1501 dicaprate plus difluoromethylornithine: a dual-agent approach targeting immunosuppressive polyamine metabolism
Ko et al. Jingyue Qiu1, Dandan Sheng1, Fei Lin2, 3*, Peng Jiang4 and Ning Shi1
WO2024086533A2 (en) Methods for treating or preventing neuroendocrine tumor formation using cdc7 inhibitors
Mantrana et al. A phase 1b study of CBP501, a novel immunogenic cell death inducer, combined with cisplatin and nivolumab in patients with advanced solid tumors
Motzer et al. 1006 ORAL Prognostic Factors for Progression-free Survival (PFS), Overall Survival (OS), and Long-term OS (LT-OS) With Sunitinib in 1,059 Patients, Treated on Clinical Trials, With Metastatic Renal Cell Carcinoma (mRCC)